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Background: Herpes simplex virus (HSV) infections are among
the most common infectious diseases in humans. The prevalence
of herpes simplex viruse type 2 (HSV-2) varies widely across
the world. Most HSV-2 infections are consequently expected to
occur after the onset of sexual activity. Genital herpes is a cause
of morbidity and increases the risk of HIV acquisition, due to
disruption of mucosal membranes.
Methods: In our descriptive study, the study group comprised
270 students with the average age of 22.2. At the beginning,
demographic data were recorded by using a questionnaire. For
serological studies 5 ml of blood sample was collected and the
serum was isolated by centrifugation. Enzyme linked immunosor-
bent assay (ELISA) was used for determination of immunoglobulin
G (IgG) antibody titer to the HSV-2. Finally the results were
analyzed by statistical methods.
Results: Overall, HSV-2-IgG antibody was positive in 63 persons
(23.3%) out of 270 subjects and they had a previous infection.
We can ﬁnd a signiﬁcant difference in prevalence between
men and women but didn’t ﬁnd any signiﬁcant relationship be-
tween students with different ﬁeld of study and their residence
(p>0.05).
Conclusion: The overall incidence of HSV-1infection in this study
was 23.3%.
Certainly information on age- and gender-speciﬁc prevalence of
HSV-2 infection is crucial to guide herpes control strategies and
prevention of HSV-2 infection should target individuals before
they become sexually active.
PP-187 Safety and immunogenicity of a HPV-16/18
AS04-adjuvanted vaccine in a phase I study in
Chinese females
Fengcai Zhu*,1, Changgui Li 2, Hongxing Pan1, Yiju Zhang1,
Dan Bi 3, Haiwen Tang3, Sanjoy Datta3. 1Jiangsu Province CDC;
2National Institute for the Control of Pharmaceutical and
Biological Products (NICPBP); 3GlaxoSmithKline Biologicals
Introduction: With age-adjusted incidence and mortality rates
up to 81/100,000 and 30/100,000 women respectively in certain
parts, cervical cancer represents a major public health challenge
in China. Immunization against oncogenic HPV has been found to
be highly efﬁcacious to prevent precancerous cervical lesions in
global vaccine studies. A Phase I study in Jiangsu Province, China,
provides the ﬁrst HPV vaccination data in local Chinese women.
Methods: In an open-label study, 30 healthy Chinese females
aged 15-45 years were, after appropriate informed consent,
recruited and vaccinated with HPV-16/18 AS04-adjuvanted vac-
cine (Cervarix™, GlaxoSmithKline Biologicals) in a 0-1-6 month
schedule. Follow-up until Month 7 was conducted for serious
adverse events (SAE), other adverse events and reactogenicity,
with data recorded by patient diary cards. Blood draws on enroll-
ment and at Month 7 enabled immunogenicity assessments for
anti-HPV-16/18.
Results: 29 subjects completed the study. One subject dropped
out due to a SAE (breast cancer) – later assessed to be unrelated
to vaccination by the investigators. The most commonly reported
solicited local symptom was pain at injection site after 65.2% of
doses (only 4.5% were considered severe) and the most commonly
reported solicited general symptoms were fatigue, headache and
myalgia (after 19.1%, 13.5% and 11.2% of doses respectively).
4 subjects reported at least one unsolicited symptom. 100%
seroconversion with high GMTs were observed in women who
completed the study at Month 7: anti-HPV-16=6187.9EL.U/ml
(CI: 4767.9, 8030.9); anti-HPV-18=2538.4 EL.U/ml (CI: 1854.0,
3475.3).
